



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Director
Bureau of Competition

AUG 10 2010

William B. Schultz, Esq.
Zuckerman Spaeder LLP
1800 M Street, NW
Suite 1000
Washington, DC 20036

Re: **Acquisition by Lupin Limited of the branded drug ANTARA from Oscient Pharmaceuticals Corporation, File No. 091-0163**

Dear Mr. Schultz:

The Commission has been conducting an investigation to determine whether Lupin Limited's consummated acquisition of assets relating to the branded drug ANTARA from Oscient Pharmaceuticals Corporation and Guardian II Acquisition Corporation and Dr. Reddy's Laboratories S.A.'s consummated acquisition of assets relating to the Abbreviated New Drug Application referencing ANTARA from Lupin may violate Section 7 of the Clayton Act or Section 5 of the Federal Trade Commission Act.

Upon further review of this matter, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

Sincerely,

Richard A. Feinstein
Director